

LECTURE PRESENTATION

Open Access

Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease

Jonathan Cechetto^{1*}, Hee Kyoung Jeon¹, Jiyeon Jang¹, Doyoon Kwon¹, Thierry Christophe¹, Priscille Brodin², Gyongseon Yang³, Jair Neto³, Lucio Freitas Junior³

From Institut Pasteur International Network Annual Scientific Meeting
Hong Kong. 22-23 November 2010

There is a pressing, global need for new therapies for neglected diseases such as Tuberculosis, Leishmaniasis and Chagas. Traditional lead discovery approaches, while effective have not been widely applied to neglected diseases as they are expensive and time consuming. At Institut Pasteur Korea, we have developed a core technology that enables the high content screening of hundreds of thousands of small molecules against the disease of interest. In doing so, we utilize relevant disease models that allow us to interrogate the disease in the context of the cell and the host-pathogen factors required for invasion, replication, persistence and release. The application of this core technology against Tuberculosis, Leishmaniasis and Chagas disease has resulted in the identification of novel, active compounds in less time and at less cost than traditional drug discovery methods. As these active compounds were identified in a cellular context, they can provide a more relevant starting point for new therapies.

Author details

¹Screening Technology Platforms, Institut Pasteur Korea, Seongnam-si, 463-400, Korea. ²Biology of Intracellular Pathogens, Institut Pasteur Korea, Seongnam-si, 463-400, Korea. ³Center for Neglected Diseases, Institut Pasteur Korea, Seongnam-si, 463-400, Korea.

Published: 10 January 2011

doi:10.1186/1753-6561-5-S1-P38

Cite this article as: Cechetto et al.: Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease. *BMC Proceedings* 2011 5(Suppl 1):P38.

¹Screening Technology Platforms, Institut Pasteur Korea, Seongnam-si, 463-400, Korea

Full list of author information is available at the end of the article

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

